Madrigal Pharmaceuticals Grants Inducement Awards to New Employees

Biopharmaceutical company awards restricted stock units to 20 new non-executive hires.

Apr. 7, 2026 at 8:34pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of pharmaceutical pill bottles, a syringe, and a clipboard with medical charts, all arranged elegantly on a clean, white seamless background. The objects are made from polished materials and use sharp, dramatic studio lighting and deep shadows to represent the abstract concepts of pharmaceutical research, clinical trials, and drug development.Madrigal Pharmaceuticals' latest inducement grants aim to bolster its team as it advances novel MASH treatments.Conshohocken Today

Madrigal Pharmaceuticals, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced that it has granted equity awards to 20 new non-executive employees as inducement awards under the terms of the company's 2025 Inducement Plan. The new employees received an aggregate of 8,079 time-based restricted stock units that will vest over four years.

Why it matters

The granting of inducement awards is a common practice for publicly traded companies to attract and retain top talent, especially in the competitive biopharmaceutical industry. These types of awards provide new employees with an equity stake in the company's future success, aligning their interests with those of shareholders.

The details

The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to grant inducement awards to new employees without shareholder approval. The restricted stock units granted will vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to the employees' continued employment.

  • The equity awards were granted on April 1, 2026.

The players

Madrigal Pharmaceuticals, Inc.

A biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).

Got photos? Submit your photos here. ›

The takeaway

The granting of inducement awards to new hires is a common practice in the biopharmaceutical industry, as companies seek to attract and retain top talent to drive innovation and growth. Madrigal's decision to grant these awards aligns with industry norms and demonstrates the company's commitment to building a strong, experienced team to advance its MASH treatment pipeline.